In a report released yesterday, Eun Yang from Jefferies reiterated a Hold rating on Amag Pharmaceuticals (NASDAQ: AMAG), with a price target of $22. The company’s shares closed yesterday at $23.20.
According to TipRanks.com, Yang is a 4-star analyst with an average return of 5.1% and a 51.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Dova Pharmaceuticals Inc, Alexion Pharmaceuticals, and Array Biopharma.
Currently, the analyst consensus on Amag Pharmaceuticals is a Hold with an average price target of $23.40, representing a 0.9% upside. In a report released yesterday, Piper Jaffray also maintained a Hold rating on the stock with a $22 price target.
.
See today’s analyst top recommended stocks >>
Based on Amag Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $20.08 million. In comparison, last year the company had a GAAP net loss of $14.07 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia.